Fennec – About the Company

Fennec Pharma (TSX: FRX.TO, OTCQB: FENCF), Inc. is a clinical-stage biopharmaceutical company focused on developing drugs to improve the lives of cancer patients. Fennec is developing Sodium Thiosulfate (STS), a chemoprotectant against the hearing loss often caused by platinum-based anti-cancer agents. Fennec partnered the STS program with the International Childhood Liver Tumor Strategy Group (SIOPEL) and the Children’s Oncology Group (COG). Both partners are engaged in funding and in the development process. The SIOPEL sponsored Phase III trial is expected to enroll 100 pediatric patients with liver cancer worldwide, of which 72 patients were enrolled as of May 10, 2013. The COG sponsored Phase III trial (ACCL0431) designed to enroll 135 pediatric patients worldwide in five different cancers completed enrollment during 2012, and data is expected to be available in the third or fourth quarter of 2013.

The Company is also developing drug candidate eniluracil (EU), which acts as an enhancer of the widely used chemotherapeutic drug 5-fluorouracil (5-FU). The Company is seeking a partnership for this Phase III-ready program.

Fennec is based out of Research Triangle Park in North Carolina.